# Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)

> **NCT00336219** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 628 (actual)

## Conditions studied

- GERD

## Interventions

- **DRUG:** Pantoprazole

## Key facts

- **NCT ID:** NCT00336219
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2006-11
- **Final completion:** 2007-04
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00336219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00336219, "Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00336219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*